INTRODUCTION
Alcohol use disorder is now regarded as a chronic relapsing and remitting disorder. Worldwide about 4% of all deaths are attributed to alcohol, which is more than the deaths caused by HIV/AIDS, violence or tuberculosis. 1 It is the leading risk factor for death in males ages 15-59, mainly due to injuries, violence and cardiovascular diseases. It is the third highest risk for disease and disability, after childhood underweight and unsafe sex. Yet, the alcohol use disorder remains a low priority in public health policy 1 . Use of alcohol is universal phenomenon in Nepalese society, as the traditional sanctions and caste-bound restraints have disappeared. Many people drink alcohol as required in cultural rituals. People make alcohol at home. The local wines (Chhyang, Tongba, Jand etc.) are included in the daily meals. In a community survey, 60 % of the Nepalese population have experienced alcohol and 41% have taken it during the last 12 months and 10 per cent are daily users of alcohol. 2 Another community based study in the eastern city of Dharan showed that the prevalence of alcohol dependence was 25.8% by CAGE questionnaire. 3 With the increasing use of alcohol in the society, alcoholism is producing a huge health care cost directly or indirectly. Alcohol use disorder is now regarded as an illness with robust biological basis. Alcohol alters the brain's structure and function which remains even after alcohol use has stopped. This is the reason people are at risk for relapse even after abstinence. Relapse rate is very high after abstinent attempts. Food and Drug Administration (FDA), USA, has approved Disulfiram, Acamprosate and Naltrexone for relapse prevention in alcohol dependence. Only Disulfiram and Naltrexone are available in Nepal. But, these drugs are not adequate for the need of the diverse group of people. Topiramate, FDA approved drug for seizure and migraine, is found to be useful in relapse prevention. Topiramate facilitates the GABA signal and inhibits the Glutamate neurons, which decreases the dopamine level in reward circuit resulting in the decrease in euphoric effect of alcohol. 4 The efficacy in reducing alcohol relapses has been seen in the placebo controlled trials. [5] [6] [7] [8] Topiramate also reduces the relapses induced by the cues 9 and the first drink following abstinence 7 thus blocking the mechanisms of relapse of alcohol. When compared with standard anticraving agent naltrexone, topiramate at 300 mg/day is as good as or even better than naltrexone in preventing alcoholic relapses 10, 11 There is an interesting observation that topiramate even at dose of 100 mg/day was significantly better than placebo 8, 12 and useful in maintaining abstinence and preventing relapses. 13, 14 This can have several implications. If clinical usefulness can be demonstrated at lower dose, dose related side effects would be fewer and treatment becomes less costly. However, we need more evidences to support these observations. Moreover, the studies in South Asian countries are scarce to get the inferences for the population. Thus, we compared the efficacy of Topiramate 100 mg with Naltrexone in Nepalese alcohol dependent individuals. We expected that the findings will be useful in guiding clinicians and adding the evidences in the field of anticraving agents. 
MATERIAL AND METHOD

Procedure:
All 173 alcohol dependent patients presented to the hospital during study period were screened for possible enrollment in the study. After exclusion, the remaining 120 patients receiving inpatient detoxification and 11 receiving detoxification on out-patient basis were discussed about the anticraving medications. Eighty five clients chose to take Naltrexone or Topiramate. Only 76 of them agreed for the informed consent. They were then assessed with Semi-structured Proforma, Readiness to Change Questionnaire 15 and Obsessive-Compulsive Drinking Scale (OCDS). 16 Patients in the Naltrexone group were prescribed a 50 mg tablet once daily with no further escalation. Patients in Topiramate group was given a 25 mg tablet in the evening which was increased to 25 mg bid in second week, and then was increased at 25mg per week up to 100mg. The participants were followed up at 0, 1, 4, 8, 12 wks. The follow up assessment was done with OCDS along with semi structured proforma. The comparison will be done between Naltrexone and Topiramate based on these outcome measures.
Outcome measure:
The outcome of the research is based on the abstinence period (The duration when there was no alcohol intake reported), and the proportion of participants abstinent at 12 weeks, the amount of alcohol consumed after the enrolment in the treatment, and the craving as shown by total OCDS score.
Tools:
The semi-structured Performa: The semi-structured Performa was used to study the socio-demographic profile and other relevant information of the patients like duration of alcohol intake, duration of alcohol dependence, average amount of alcohol intake in atypical day, previous attempts to quit alcohol if any, any co-morbid medical problems or medical problems related to alcohol use and the family history of alcohol dependence. The semi-structured Performa for follow up included the duration of abstinence, the amount and the frequency of drinking if restarted. Readiness to Change Questionnaire: 15 The Readiness to Change Questionnaire (RCQ) is a short and useful measure to find out the drinkers stage of change based on the model developed by Prochaska and DiClementel. It is a 12-item instrument. All items are scored on a 5-point rating scale ranging from: -2 (Strongly disagree),-1(Disagree) 0 (Unsure), +1 (Agree), +2 (Strongly agree). To derive the readiness to change score, the combined contemplation and action stages score were added with the precontemplation score with reverse sign ( -changed to + and + changed to -). 16 The OCDS is a modified version of the YaleBrown Obsessive Compulsive Scale (Modell JG et al 1992). The scale is a valid instrument to measure craving for alcohol. It measures various aspects of craving like the urge to drink alcohol, thoughts about alcohol and the struggle to control the urge. It consists of 14 items which takes about five minute to fill up.
Obsessive-compulsive drinking scale (OCDS):
Statistical analyses:
Thus obtained data was fed into the computer and a master sheet was produced in the Windows Excel 2010. Further analyses were done in SPSS 17.0. The abstinence period is presented in median, the amount of alcohol consumed after the enrolment in the treatment is presented in median with interquartile range.
Ethical issues:
The approval for the research was taken from the Ethical Review Board of the Institute. The participants were well informed about the advantages and the disadvantages of taking or not taking medicines, including the cost of the treatment. The decision to take medication was taken with the active participation of the patient as well as family member. The informed consent was taken from all the participants. They knew that they can withdraw the consent anytime during the study and that the withdrawal from the study will not affect patient care in the days to come. .651) at the end 12 wk among Nepalese population. Our finding is similar to the finding in the study of Danilo Antonio Baltieri which reports that at the end of their study (12th week), although the proportion of subjects completely abstinent was higher in the topiramate group, this difference was no longer statistically significant (P = 0.08). 12 However, the proportion of the subjects maintaining abstinence at the end of 12 wks is lower in our participants than in the Baltieri's sample (27% Vs 47.05%) 12 . The difference in the abstinence rate between the Baliteri group and our Topiramate group may be because our sample is hospital based and was not randomized. in Narayana's sample, the high rate of abstinence at 12 months may be because their study participants were all Indian army who will be invalidated of their service if they get relapse within one year of the treatment. In the analysis of Obsessive Compulsive Drinking Scale score, Topiramate is found to be significantly associated with the reduction in craving due to alcohol as the decrease in OCDS score is highly significant at 4, 8 and 12 wks (p=0.001). This is in accordance to the findings from Paparrigopolous, who used 75 mg Topiramate. 13 In this study, the reduction from the baseline OCDS score is highly significant in each follow up. Similarly in other studies 10, 12 using OCDS, the decrease in mean score is significant at the end of the study. In our participants, though topiramate is comparable to naltrexone at 1 st and 2 nd month, topiramate out performed Naltrexone at 3 rd month (p=0.015) in reducing craving as measured by OCDS. Our observation is different from that of other similar studies. The observation by Baltieri in Brazil shows that both Naltrexone (50 mg) and Topiramate (300 mg) were similar in terms of reduction of mean scores on OCDS (F = 0.03, P = 0.97) at 12 weeks. 12 Similarly, the findings from the Spanish investigator Gerardo Flórez also reveal that Naltrexone and Topiramate were similar in terms of reducing OCDS score at the end of 12 wks (p=0.514). 10 Our finding needs to be cautiously interpreted as OCDS is not validated into Nepalese context there is nonrandom allocation of the medicines to the participants. We admit that we have many limitations in this work. We conducted the study in the hospital setting and we could not allocate the medicines randomly due to ethical issues. So, the results should be interpreted cautiously. Nonetheless, our sample represents dialy clinical sample and this work has given some insight that even lower dose Topiramate is of use in the treatment of alcoholism in our patients.
RESULT
CONCLUSION:
Topiramate 100 mg is as efficacious as Naltrexone 50 mg in maintaining abstinence for 12 weeks, in decreasing the daily alcohol consumption, and in reducing craving at 12 weeks. Our study contributes important new data on the efficacy of Topiramate in the treatment of Alcohol Dependence, despite few limitations. The results of the study demonstrate the response of the Nepalese population presenting with Alcohol Dependence Syndrome to Topiramate or Naltrexone as relapse prevention agent. Thus, this finding further demands the need of well-designed controlled clinical trials in our population to prove our observation.
